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Expanded CURB-65: a new score 
system predicts severity of 
community-acquired pneumonia 
with superior efficiency
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Alessio Farcomeni3, Mario Venditti3, Ying-li Zhao1, Shu-ya Luo1, Xiao-jun Dong1  
& Marco Falcone3
Aim of this study was to develop a new simpler and more effective severity score for community-
acquired pneumonia (CAP) patients. A total of 1640 consecutive hospitalized CAP patients in Second 
Affiliated Hospital of Zhejiang University were included. The effectiveness of different pneumonia 
severity scores to predict mortality was compared, and the performance of the new score was validated 
on an external cohort of 1164 patients with pneumonia admitted to a teaching hospital in Italy. 
Using age ≥ 65 years, LDH > 230 u/L, albumin < 3.5 g/dL, platelet count < 100 × 109/L, confusion, 
urea > 7 mmol/L, respiratory rate ≥ 30/min, low blood pressure, we assembled a new severity score 
named as expanded-CURB-65. The 30-day mortality and length of stay were increased along with 
increased risk score. The AUCs in the prediction of 30-day mortality in the main cohort were 0.826 
(95% CI, 0.807–0.844), 0.801 (95% CI, 0.781–0.820), 0.756 (95% CI, 0.735–0.777), 0.793 (95% CI, 
0.773–0.813) and 0.759 (95% CI, 0.737–0.779) for the expanded-CURB-65, PSI, CURB-65, SMART-COP 
and A-DROP, respectively. The performance of this bedside score was confirmed in CAP patients of 
the validation cohort although calibration was not successful in patients with health care-associated 
pneumonia (HCAP). The expanded CURB-65 is objective, simpler and more accurate scoring system for 
evaluation of CAP severity, and the predictive efficiency was better than other score systems.
Community-acquired pneumonia (CAP) is one of the most common infectious diseases needing hospitaliza-
tion. Inappropriate treatment of outpatient or delay of admission of CAP patients to ICU has been shown to be 
associated with increased mortality1,2, and it is important for physicians to identify patients who are experienc-
ing severe pneumonia with probably worst prognosis as early as possible. Moreover, pneumonia occurring in 
patients living in the community but with a recent exposure to the healthcare system (i.e. patients with recent 
hospitalization, undergoing hemodialysis, or living in nursing homes or long-term care facilities) has been named 
healthcare-associated pneumonia (HCAP). Several studies suggest that this category of pneumonia has a higher 
mortality than CAP3,4.
Multiple serum biomarkers and several established risk scores have been used to assess the severity of CAP 
to improve management of CAP patients. Pneumonia Severity Index (PSI) was the first scoring system, which 
consists of twenty clinical and laboratory parameters and is recommended by the American Thoracic Society 
(ATS)/Infectious Diseases Society of America (IDSA)5. CAP patients can be assigned into 5 risk classes. Patients 
with class IV–V should be hospitalized for treatment as the prognosis deteriorates along with increasing risk 
class. Although the PSI exhibits a high discriminatory power for assigning appropriate risk class, it is compli-
cated to calculate and limits clinical application. Later, the British Thoracic Society recommended a system using 
Confusion, Urea, Respiratory rate, Blood pressure plus age ≥ 65 years (CURB-65) for CAP management6. CURB-
65 simplifies the scoring system compared with PSI, but at the expense of reducing sensitivity for the 30-day mor-
tality. In addition, both CURB-65 and PSI possess the deficiency in the predictive specificity. For instance, many 
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young patients were incorrectly categorized as low risk. More recently, SMART-COP score (Systolic blood pres-
sure, Multilobar infiltrates, Albumin, Respiratory rate, Tachycardia, Confusion, Oxygen and pH) was derivated 
in Australia. SMART-COP emphasizes predicting the need for ventilatory/vasopressor support. It is still compli-
cated to calculate multiple points for different variables and age-adjusted cut-off 7, and a further score (A-DROP: 
Age, Dehydration, Respiratory failure, Orientation disturbance, Systolic blood pressure) was developed in Japan8. 
All of the scores can help determine whether a patient needs to be hospitalized or even admitted to the ICU9.
Clearly, a simpler, but more reliable score system is needed. In this study, we evaluated multiple risk factors 
contributing to the 30-day mortality in hospitalized pneumonia patients coming from the community. Then we 
developed a simpler and more effective scoring system by expanding CURB-65, to evaluate its efficiency com-
pared to currently available scores for severity assessment.
Materials and Methods
Study population. We retrospectively analyzed consecutive patients with diagnosis of CAP between January 
2010 and December 2013 hospitalized at Second Affiliated Hospital, Zhejiang University School of Medicine. The 
definition of CAP/HCAP for this study followed the ATS and the IDSA guidelines10,11. Patients were excluded if 
they had HIV infection or if had been in hospital within the previous 7 days3. Comorbidities were documented, 
defined as presence of one or more of the following diseases: congestive heart failure, chronic obstructive pul-
monary diseases (COPD), chronic renal diseases, chronic liver diseases, cerebrovascular diseases, malignancy 
(solid tumor or hematological malignancy), or diabetes mellitus12. The Ethics Committee of the involved hospi-
tals approved this study.
Clinical data. We collected all the data from each subject, including demographic factors, co-morbidity con-
ditions, physical examination and laboratory/radiologic findings. The laboratory findings were analyzed within 
24 h after admission.
Definition of expanded-CURB-65, PSI, CURB-65, SMART-COP, and A-DROP. Severity of 
pneumonia was assessed using the CURB-65 score6, PSI score5, SMART-COP score7, A-DROP score8, and 
expanded-CURB-65 (CURB-65, lactate dehydrogenase, platelet, and albumin) we proposed, respectively.
External validation. The new score obtained was validated on an external prospective cohort of adult 
patients with pneumonia hospitalized in a 1200 bed teaching hospital (Policlinico Umberto I-Rome) from Italy. 
Study methods were previously reported13,14. Briefly, we prospectively collected data of all episodes of pneumonia 
during the period between January 2013 and March 2014. All patients were followed-up to discharge or death.
Statistical analysis. Chi-square test and Fisher’s exact test were used to determine the association between 
qualitative/categorical variables. Continuous variables were expressed as mean ± standard deviation (SD) and 
compared between groups using one-way analysis of variance. Correlations between two continuous variables 
were assessed with the Pearson correlation. Distribution of the analyzed continuous variables for normality was 
tested with the Kolmogorov-Smirnov test. Multiple logistic regression analysis was used to determine independ-
ent risk factors for mortality. The odds ratio (ORs) and corresponding 95% confidence intervals (CIs) for each 
variable were calculated. We evaluated discrimination using receiver operating characteristic curves (ROC) and 
compared the areas under the ROC curves (AUCs) for the different scores, adjusting the probability using the 
Sidak method. The calibration of the model was evaluated by the godness-of-fit Hosmer-Lemeshow χ 2 statistic. 
All tests were two-tailed, and a P value < 0.05 was considered significant. Computations were carried out with 
SPSS 20.0 for Windows (R version 3.0.2) and STATA v.12.
Results
Patient characteristics. A total of 1879 hospitalized patients with CAP were evaluated in this retrospective 
study, and 1640 of them were finally eligible for analysis. The general characteristics of these patients are shown 
in Table 1. A mean age was 64 ± 19 years and 59.6% of patients were male. Overall, 37.6% of patients were accom-
panied by one or more coexisting illnesses, including congestive heart failure (10%), COPD (8.3%), chronic renal 
diseases (5.1%), chronic liver diseases (2.5%), cerebrovascular diseases (6.6%), malignancy (4.6%) and diabetes 
mellitus (7.9%). The median length of stay (LOS) was 10 (IQR 7–15) and the 30-day mortality was 8.48%.
Factors related to the mortality and LOS. Thirteen potential predictive variables including all the com-
ponents of CURB-65 score were selected and assessed using X2 test and uni- and multivariate logistic regression, 
respectively (see Table 2). We found that elevated serum LDH level (> 230 u/L), thrombocytopenia (platelet count 
< 105/mL) and hypoalbuminemia (albumin level < 3.5 g/dL) were independent risk factors for death at multivar-
iate analysis: the Table 3 describes the prevalence of these risk factors in different risk classes of the CURB-65 and 
PSI scores.
The new score system proposed for evaluating pneumonia severity. We created a new score sys-
tem, which expands CURB-65 and consists of 8 parameters, named expanded-CURB-65 including age ≥ 65 years, 
LDH > 230 u/L, Albumin < 3.5 g/dL, Platelet count < 100 × 109/L, Confusion, Urea > 7 mmol/L, Respiratory 
rate ≥ 30 /min, low systolic (< 90 mmHg) or diastolic (≤ 60 mmHg) Blood pressure. The expanded-CURB-65 
score was categorized into three classes as follows: 0–2 as low risk, 3–4 intermediate risk, and 5–8 high risk. 
Accordingly, patients with one of three tiers of scores should be treated either as outpatient, or inpatients in hos-
pital ward or ICU, respectively.
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Demographic data
Age, mean (± SD), y 64 ± 19
Age ≥ 65 years, N (%) 881 (53.7)
Male, N (%) 977 (59.6)
Comorbidities, N (%) 616 (37.6)
 Congestive heart failure 164 (10.0)
 COPD 136 (8.3)
 Chronic renal diseases 83 (5.1)
 Chronic liver diseases 41 (2.5)
 Cerebrovascular diseases 109 (6.6)
 Malignancy 75 (4.6)
 Diabetes mellitus 130 (7.9)
Physical examination findings N (%)
 Confusion 85 (5.2)
 Respiratory rate ≥ 30 /min 39 (2.4)
 Heart rate ≥ 125 /min 36 (2.2)
Blood pressure (systolic < 90 mmHg or 
diastolic ≤ 60 mmHg) 127 (7.7)
LOS (interquartile range) 10 (7–15)
30-day mortality, N (%) 139 (8.48)
Table 1.  Baseline characteristics of CAP patients.
Risk factor
Univariate analysis
Multivariate logistic regression 
analysis
OR 95% CI p β OR 95% CI P
Age ≥ 65 years 2.89 1.93–4.30 < 0.01 0.67 1.95 1.25–3.03 < 0.01
BUN > 7 mmol/L 4.82 3.39–6.92 < 0.01 0.98 2.68 1.79–4.01 < 0.01
Confusion 7.24 4.45–11.76 < 0.01 1.48 4.39 2.52–7.65 < 0.01
Respiratory rate ≥ 30 /min 6.61 3.35–13.04 < 0.01 1.34 3.82 1.68–8.74 < 0.01
Blood pressure 
(SBP < 90 mmHg or 
DBP ≤ 60 mmHg) 
3.01 1.87–4.85 < 0.01 0.63 1.88 1.06–3.32 0.03
Pulse ≥ 125 beats/min 3.78 1.74–8.21 < 0.01 0.91 2.49 0.95–6.55 0.06
Serum LDH level > 230U/L 3.65 2.52–5.29 < 0.01 0.73 2.07 1.37–3.11 < 0.01
Albumin level < 3.5 g/dL 3.59 2.36–5.47 < 0.01 0.72 2.06 1.29–3.28 < 0.01
Platelet count < 105/mL 4.94 3.42–7.13 < 0.01 1.05 1.05 1.88–4.32 < 0.01
Glucose level ≥ 11.1 mmol/L 2.38 1.48–3.84 < 0.01 0.13 0.13 0.65–2.02 0.65
WBC count < 4 or > 10 × 109/L 1.49 1.05–2.11 < 0.01 0.12 0.12 0.76–1.70 0.55
C-reactive protein level 
> 150 mg/L 2.11 1.46–3.06 < 0.01 0.21 0.21 0.80–1.90 0.06
Table 2.  Univariate and multivariate analyses of features associated with 30-day mortality in CAP patients.
Subgroup
Patients, N 
(%)
Serum 
LDH > 230 u/L, 
N (%)
Hypoalbuminemia, 
N (%)
Thrombocytopenia, 
N (%)
PSI class
 I–II 693 (42.26) 219 (31.60) 276 (39.83) 57 (8.23)
 III 386 (23.54) 153 (39.64) 227 (58.81) 59 (15.28)
 IV–V 561 (34.21) 268 (47.77) 378 (67.38) 144 (25.67)
CURB-65 class
 0–1 1215 (74.09) 417 (34.32) 599 (49.30) 147 (12.10)
 2 341 (20.79) 172 (50.44) 223 (65.40) 87 (25.51)
 3–5 84 (5.12) 51 (60.71) 59 (70.24) 26 (30.95)
Table 3.  The prevalence of hypoalbuminemia, thrombocytopenia and high serum LDH in different risk 
classes of the CURB-65 and PSI scores in CAP patients.
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The performance in predicting the 30-day mortality and LOS by all the scoring systems is shown in Table 4, 
respectively. Expanded-CURB-65 scores were also positively associated with median LOS: score 0–2 (low risk) 
with 9 days (IQR 7–13), score 3–4 (intermediate risk) with 12 days (IQR 8–18), and score 5–8 (high risk) with 14 
(IQR 9–22) (Table 4).
Finally, as described in Fig. 1, we analyzed the discrimination power of all score systems for predicting the 
30-day mortality using ROC curves. Interestingly, the overall sensitivity and specificity of expanded-CURB-65 
were superior (AUC = 0.826, 95% CI, 0.807–0.844) to other score systems, of which the AUCs were 0.801 (95% CI, 
0.781–0.820), 0.756 (95% CI, 0.735–0.777), 0.793 (95% CI, 0.773–0.813), and 0.759 (95% CI, 0.737–0.779) for PSI, 
CURB-65, SMART-COP and A-DROP, respectively. The expanded-CURB-65, CURB-65, A-DROP, and PSI were 
Subgroup Patients, N (%)
LOS, Median 
(IQR)
Mortality, N 
(%)
PSI class
 I–II 693 (42.26) 9 (6–13) 9 (1.30)
 III 386 (23.54) 12 (7–15) 17 (4.40)
 IV–V 561 (34.21) 15 (8–18) 113 (20.14)
CURB-65 class
 0–1 1215 (74.09) 9 (7–14) 55 (4.53)
 2 341 (20.79) 12 (8–18) 46 (13.49)
 3–5 84 (5.12) 12 (7–17.75) 38 (45.24)
SMART-COP class
 0–2 1406 (85.73) 10 (7–14) 77 (5.48)
 3–4 211 (12.87) 12 (8–19) 48 (22.75)
 5–8 23 (1.40) 10 (5–16) 14 (60.87)
A-DROP class
 0–1 1281 (78.11) 9 (7–14) 61 (4.76)
 2 280 (17.07) 11 (8–17.75) 45 (16.07)
 3–5 79 (4.82) 10 (7–17) 33 (41.77)
Expanded CURB-65 class
 0–2 1052 (64.15) 9 (7–13) 27 (2.57)
 3–4 497 (30.30) 12 (8–18) 74 (14.89)
 5–8 91 (5.55) 14 (9–22) 38 (41.76)
Table 4.  Outcome of subgroups for PSI, CURB-65, SMART-COP, A-DROP and expanded CURB-65 scores 
in CAP.
Figure 1. ROC curves for five scoring systems in the main cohort of CAP patients. 
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validated in CAP (P = 0.336, 0.157, 0.178, 0.576, respectively) by the Hosmer-Lemeshow test after Bonferroni 
correction. SMART-COP was not validated among CAP patients after Bonferroni correction (P = 0.008).
Validation of the new score system proposed. The performance of the expanded-CURB was evaluated 
in a validation cohort of 1164 patients with pneumonia; out of these 39.5% fulfilled HCAP definition. Compared 
to the main cohort, these patients were older (mean age 75, P < 0.001) and had a slightly higher 30-day mortality 
(17.3%, P < 0.001). The performance of this expanded CURB-65 score was confirmed well in all patients of the 
validation cohort (AUC 0.78, 95% CI, 0.746–0.814). Among CAP patients, AUCs for prediction of 30-day mor-
tality were 0.772 (95% CI, 0.710–0.834), 0.748 (95% CI, 0.691–0.806), 0.663 (95% CI, 0.599–0.728), 0.716 (95% CI, 
0.655–0.776), and 0.679 (95% CI, 0.602–0.755) for the expanded–CURB–65, PSI, CURB-65, SMART-COP and 
A-DROP, respectively. For HCAP patients, AUCs were 0.736 (95% CI, 0.687–0.784), 0.686 (95% CI, 0.635–0.737), 
0.675 (95% CI, 0.626–0.724), 0.700 (95% CI, 0.650–0.751), and 0.747 (95% CI, 0.703–0.791), respectively. Once 
again, there were no significant differences in term of AUCs between the main cohort and the validation cohort. 
Using the Hosmer-Lemeshow test, we found that expanded-CURB-65 is validated on CAP (P = 1.000 after 
Bonferroni correction), but not on HCAP patients (P = 0.0175 after Bonferroni correction). In addition, we had 
satisfactory calibration of CURB-65, SMART-COP and A-DROP (P = 0.411, 0.225, 0.695, respectively) among 
CAP patients, but not of PSI (P = 0.0035). Among HCAP patients, we had good calibration of CURB-65 and 
A-DROP (P = 0.740 and 1.000, respectively) but not of PSI (P < 0.001) and SMART-COP (P = 0.0095). Figure 2 
summarizes ROC curves of all score systems in both CAP and HCAP groups, respectively.
Discussion
The purpose of our study was to establish and evaluate a new simpler and more efficient scoring system for assess-
ing severity of CAP. We first identified 8 independent risk factors closely related to the mortality of CAP patients. 
Then, a new severity score termed expanded-CURB-65, consisting of these 8 variables, was tested in this cohort. 
Our results showed that this new system was relatively simpler, but more efficient than those early established, and 
its efficacy was confirmed in an external validation cohort.
Three key factors seem to improve performance of CURB-65 score: LDH levels, thrombocytopenia, and 
hypoalbuminemia. LDH is a cytoplasmatic enzyme expressed in nearly all types of cells of the body. It is released 
into blood when cell experiences injury or death caused by ischaemia, excess heat or cold, starvation, dehydration, 
injury, bacterial toxins, drugs and chemical poisonings15–17. Because of higher concentration expressed in various 
organs/tissues, the leakage of LDH from even a small scale of injured tissue can result in a significantly elevated 
serum level15. LDH has been used as an indicator of cellular injury induced by various etiologies. Previous studies 
have demonstrated that the elevated LDH in serum, especially in bronchoalveolar lavage (BAL) and pleural fluid 
can help determine the extent of lung tissue damage and inflammation such as pulmonary embolism, P. carinii 
pneumonia, tuberculosis, bacterial pneumonia, influenza A18–23. Ewig reported that the increased serum LDH 
values were associated with increased mortality in 92 CAP patients24. The higher serum LDH level indicates the 
more severe complications and the worse prognosis.
Thrombocytopenia and hypoalbuminemia also serve as markers indicating that patients need ICU admission 
and may result in a higher mortality in hospitalized CAP patients25–28. Platelets, hemostasis, and wound healing 
are all involved in inflammatory lung diseases29,30, and appearance of thrombocytopenia, which results in coag-
ulation derangements, is associated with dismal prognosis in CAP patients and it is one of the minor criteria for 
severe CAP by IDSA/ATS10. Hypoalbuminemia, which can be caused by malnutrition, liver cirrhosis, or infection 
process, contributes to an increased mortality in hospitalized patients31, and several studies have identified a close 
correlation between serum albumin concentration and mortality in CAP patients6,7,28,32,33. Therefore, expand-
ing CURB-65 through including LDH, thrombocytopenia and hypoalbuminemia levels can increase the effi-
ciency of predicting the severity in CAP patients. Recently, the studies suggested that either pre-existing diabetes 
Figure 2. ROC curves for five scoring systems in CAP and HACP patients in the validation cohort. 
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or acute hyperglycemia without pre-existing diabetes was associated with longer LOS and higher mortality in 
CAP patients34,35. However, our data did not show a positive correlation between hyperglycemia and the 30-day 
mortality.
During last decades, several quantitative score systems, including PSI, CURB-65, SMART-COP and A-DROP, 
have been developed to assess pneumonia severity. PSI, which draws the score from 20 variables, is accurate 
in predicting the 30-day mortality, but its complexity limits clinical application. Contrarily, CURB-65 features 
simplicity. However, the patient’s age and complications in both PSI and CURB65 carry heavier weight, under-
estimating the potential severity in young patients and falsely referring the elderly CAP patients as severe36. 
Moreover, both PSI and CURB-65 scores did not exhibit good performance in stratifying risk of death among 
patients with community-onset pneumonia but fulfilling HCAP definition37. In addition, neither PSI nor CURB-
65 was designed to identify patients who need to be referred to the ICU, and SMART-COP was aimed to com-
pensate this function7. The SMART-COP, which is processed by logistic regression analysis, provides superior 
accuracy for prediction of the need for intensive respiratory or vosopressor support, but it is a still complicated 
process to calculate multiple points for different variables and age-adjusted cut-off. For CAP patients in Asia, 
A-DROP is a simple modified version of the CURB-65 and it is recommended by Japan Respiratory Society (JRS), 
but the ROC curve for A-DROP is similar to CURB-6512.
Compared to CURB-65 and other assessment tools, the expanded-CURB-65 score, which extends independ-
ent risk factors to 8 variables in assessing CAP severity, significantly improves identifying high-risk patients, 
through decreasing the relative weight of age and blood pressure, and eliminating the use of imaging and comor-
bid illnesses in the calculation. The only gap remains among HCAP patients, since data from validation cohort 
did not confirm a good performance of the score in this subgroup of patients. HCAP comprises a heterogene-
ous population of patients with more comorbidities, recent healthcare contacts and increased risk of multidrug 
resistance pathogens. Probably this category of patients is quite different to that considered as “classical” CAP, 
and some authors have proposed to reconsider this epidemiological entity38. The findings of our study confirm 
the need of further characterization of the subgroup of patients fulfilling HCAP definition, to improve the initial 
assessment and management of this category.
There are a few limitations in this study. First, this is a retrospective single center study and no outpatients 
were included. Second, although the blood samples were collected as soon as patients were admitted, there were 
variations in the timing of collecting. In addition, we didn’t include the ICU admission as a risk factor because 
a portion of patients died before reaching the ICU due to the shortage of ICU resources and financial support 
in developing countries. However, our data were validated on a prospective cohort of patients with pneumonia 
observed in a geographic area completely different in term of demographic features, predisposing factors, and 
hospital resources. Thus we believe that it is the major strength of our study.
In conclusion, our expanded CURB-65 is a relatively simpler and more effective marker in assessing the sever-
ity of hospitalized patients with CAP. Despite the encouraging results, further validation is warranted in future 
multicenter large prospective studies.
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